Liminatus Pharma shares are trading lower. The company announced it has engaged Synex Consulting to support the clinical development of IBC101, CD19xCD22 bivalent CAR-T cell therapy candidate.

Benzinga Newsdesk www.benzinga.com Positive 56.7%

Neg 0% Neu 0% Pos 56.7%

Comments

No comments yet. Be the first!